Brief: Fortress Biotech And Cyprium Therapeutics Announce U.S. FDA Approval Of Zycubo® (Copper Histidinate), The First And Only Approved Treatment For Menkes Disease In The United States

Fortress Biotech

13/01/2026 12:48

Jan 13 (Reuters) - Fortress Biotech Inc FBIO.O:

FORTRESS BIOTECH AND CYPRIUM THERAPEUTICS ANNOUNCE U.S. FDA APPROVAL OF ZYCUBO® (COPPER HISTIDINATE), THE FIRST AND ONLY APPROVED TREATMENT FOR MENKES DISEASE IN THE UNITED STATES

FORTRESS BIOTECH INC - CYPRIUM ELIGIBLE FOR UP TO $129 MILLION IN MILESTONES

FORTRESS BIOTECH INC - RARE PEDIATRIC DISEASE VOUCHER TO BE TRANSFERRED TO CYPRIUM

Source text: ID:nGNXbm5sCh

Further company coverage: FBIO.O

 ((Reuters.Briefs@thomsonreuters.com;))